^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CTA30X UCAR-T

    i
    Other names: CTA30X UCAR-T
    Associations

    News

    Trials
    Company:
    Nanjing Bioheng Biotech
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2years
    UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies (clinicaltrials.gov)
    P1, N=0, Withdrawn, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | N=72 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CTA30X UCAR-T